rhTPO + CsA vs CsA in the Treatment of LR-MDS With Thrombocytopenia

Starting soon · Phase 3

Conditions studied: Lower-risk Myelodysplastic Syndromes

In brief

This study aims to compare the efficacy and safety of recombinant human thrombopoietin (rhTPO) + cyclosporine (CsA) and CsA monotherapy in the treatment of lower-risk myelodysplastic neoplasms with thrombocytopenia.

Key facts

Study ID

NCT07653581

Run by

Peking Union Medical College Hospital

People needed

78

Starts

2026-06-01

Expected to finish

2029-12-01

Last updated by the study team

2026-06-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years old;
• Confirmed diagnosis of lower-risk MDS;
• Platelet ≤ 30×109/L, or < 50×109/L and accompanied by bleeding events;
• Baseline liver and kidney functions <2 ULN;
• Signed the informed consent form;
• ECOG 0-2;

You may not qualify if…

• History of leukemia or stem cell transplantation, treatment-related MDS or malignant tumors;
• With splenomegaly or myelofibrosis;
• Infections or bleeding that cannot be controlled by standard treatment;
• Any concurrent malignant tumors within the past 5 years, or basal cell carcinoma of the skin at the local site;
• History of thromboembolic events, heart attack or stroke and current use of anticoagulants;
• Previously received cyclosporine (CsA) or ATG within 6 months;
• Previously used IL-11, rhTPO or TPO-RA;
• Pregnant or lactating women;
• Participated in other clinical trials within 3 months.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.